Abstract:Dear Editor, Chronic hepatitis B virus (HBV) infection affects about 844 million people worldwide, with two million annual deaths and a rising incidence. Persistent HBV infection may lead to liver inflammation and fibrosis, a leading risk for liver transplantation and hepatocellular carcinoma.1 However, few treatment options for controlling HBV-related liver inflammation are currently available. The limited understanding on corresponding mechanisms impedes the discovery of rational therapeutics targeting on liver inflammation and fibrosis. Thus, we conducted a single-cell transcriptomic study2 to better understand the mechanisms underlying chronic HBV-related liver inflammation and to enable the discovery of therapeutic targets. Liver biopsies from six chronic HBV patients with different grades of liver inflammation were included in the present study (Figure S1; Table S1). Single-cell RNA sequencing of biopsied liver tissues was performed. Functions and cross-talks of single cells were also investigated (provided in Supplementary Materials). Based on around 24,000 single cells, we obtained 12 cell clusters. Among them, T cell population was the most abundant (Figure 1; Figure S2). By assigning the samples to different grades of inflammation (G), no apparent perturbation was observed in respect to the fractions of cells between grades G1 and G2 (Table S2). We further classified the 16, 386 T cells into nine cell subclusters, six of which varied significantly as liver inflammation progresses (Figure 2A,B). We then assigned them to known lineages based on marker genes (Figure 2C,D; Table S3). Concisely, T7 and T6 were annotated as CD8+ mucosal-associated invariant T (MAIT) cells. T2 and T0 were identified as activated and exhausted CD8+ T cells, respectively. Most interestingly, MAIT cells, especially T7, decreased, while the ratio of T6 versus T7 increased in grade G2. Moreover, T7 dominated in grade G1 (95.20%) (Figure 2E and Figure S3A,B). The above findings were confirmed by additional single-cell RNA sequencing data from liver samples of HBV-infected patients with grades G1 (n = 4) and G2 (n = 4) (Figure S3C,D).2 T6 was assumed to be developed from T7 (Figure 2F), with genes such as CCL3L1, PTMS, KLRG1 and GADD45B responsible for the transition (Figure S3E). Additionally, macrophage subcluster Ma3, inclined to have M2 signature, increased in grade G2 (Figure S4). Although no apparent perturbations were observed for the fractions of different cell types, T cell subpopulations were remodeled during the progression from grades G1 to G2. We further confirmed the presence of two MAIT cell populations by immunofluorescence, and annotated them as CD3+SLC4A10+TNFAIP3+ (T7) and CD3+SLC4A10+TNFAIP3− (T6) MAIT cells (Figure 3). T7 may have stronger direct anti-viral functions. Firstly, intrahepatic MAIT cells have been reported to be the most important innate effector cells secreting anti-viral cytokine IFN-γ,3 and T7 demonstrated up-regulated pathways ‘interferon gamma secretion’ and ‘regulation of response to interferon gamma’ (Figure 4A). Secondly, T7 may have stronger type-17 function of MAIT cell populations that might have a certain antiviral role,4 evidenced by the up-regulation of pathways such as ‘T helper 17 type immune response’. Moreover, T7 may be stronger mediators of immune responses. On one hand, T7 may increase the anti-viral capability of hepatocytes by ligand-receptor pairs such as ‘FcRn complex_ALB’ (Figure 4B), where FcRn was reported to increase the sensitivity of hepatocyte to toxicity.5 Pathways such as ‘Toll-like receptor 4 signaling pathways’ that can reduce HBV replication in an IFN-independent manner in hepatocytes6 was also up-regulated in T7. On the other hand, T7 may be more active in cytokine production and recruiting activated CD4+ and CD8+ T cells,7 evidenced by up-regulated pathways such as ‘positive regulation of CD4 positive alpha beta T cell activation’. Then, T7 may assist virus infection control via activating NK cell and CD8+ T cell mediated immune responses through cross-talks for T7-NK cells and T7-T2, evidenced by ligand-receptor pairs such as ‘HLA-C_KIR2DL3’ and ‘HLA-A_KIR3DL1’, which were reported to function as helper masters to antiviral T cell responses.8 Such results indicated that MAIT cell population T7 may have active antiviral functions for reducing HBV replication in grade G1. Immunofluorescence results for additional two biopsies obtained from two G1 patients (Figure S5) further validated the presence of T7 in grade G1. We speculated impaired antiviral roles of T6 in grade G2 from the down-regulation of corresponding pathways mentioned above, and the decrease in pathways ‘regulation of defense response to virus’ and ‘innate immune response’ (Figure 4A). Such results implied the existence of MAIT cell dysfunction in grade G2. We also observed a sharp decrease of activated CD8+ T cells, and a sharp increase of CD8+ exhausted T cells in grade G2. T cell exhaustion, in together with immune dysfunction of T6, may contribute to the inadequate HBV-specific immune responses and inadequate infection control in grade G2. The increased M2-type macrophage activation (Ma3) also implied the impaired immune response9 in grade G2. Bacterial superantigens resulting from the leaky gut of chronic HBV patients can make MAIT cells hyperactive and exhausted, which will lead to immunosuppression and increases the risk of secondary opportunistic infections.10 Thus, the dysfunction of MAIT cells T6 and exhaustion of CD8+ T cells may also provide an explanation for the progression of HBV-related inflammation in grade G2. Moreover, MAIT cells demonstrated extensive interactions with other immune cells (provided in Supplementary Materials). In conclusion, our study reported the remodelling of T cell subpopulations and the presence of two MAIT cell populations that may contribute to HBV-related liver inflammation for the first time. MAIT cell population T7 may have active roles in assisting virus clearance via direct anti-viral functions and mediating immune responses, which was impaired in T6, the proportion of which in CD8+ MAIT cells increased in grade G2. The sharp decrease of active CD8+ T cells, MAIT cell dysfunction in together may contribute to the inadequate HBV-specific immune responses in grade G2. Inspired from the decrease of MAIT cells and increased ratio of T6 versus T7 during liver inflammation progression, MAIT cells may act as a potential target for controlling HBV-related liver inflammation in future studies. However, studies using more samples are required to confirm the findings between G1 and G2 reported in this study. The present study was funded by grants from the National Natural Science Foundation of China (grant numbers: 31870839 and 81870426), the Natural Science Foundation of Zhejiang Province (grant numbers: LZ20H290002 and LY22C010001), the National Youth Top-notch Talent Support Program (grant number: W02070098), the HangZhou Medical and Health Technology Project (grant number: Z20200052), and the Innovation Team and Talents Cultivation Program of National Administration of Traditional Chinese Medicine (grant number: ZYYCXTD-D-202002). The authors declare that they have no conflict of interest. This work was supported by the key medical disciplines of Hangzhou and the Westlake Laboratory (Westlake Laboratory of Life Sciences and Biomedicine). The authors thank all the participants who helped collecting liver biopsies. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.

Abstract:Liver TransplantationVolume 27, Issue 3 p. 459-460 Letters to the editor Presence of Macrosteatosis In Vivo Determined the Survival Status of Rats After Liver Transplantation Zhengtao Liu Ph.D., Corresponding Author Zhengtao Liu Ph.D. liuzhengtao@zju.edu.cn orcid.org/0000-0002-6232-4778 Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China NHC Key Laboratory of Combined Multi-organ Transplantation, Key Laboratory of the Diagnosis and Treatment of Organ Transplantation, CAMS, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China Key Laboratory of Organ Transplantation, Zhejiang Province, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China Both authors contributed equally to this work. Address reprint requests to Zhengtao Liu, Ph.D., and Shusen Zheng, M.D., Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310 003, China. Telephone/FAX: +86 571 87236570; E-mail: liuzhengtao@zju.edu.cn; shusenzheng@zju.edu.cnSearch for more papers by this authorWenchao Wang M.D., Wenchao Wang M.D. NHC Key Laboratory of Combined Multi-organ Transplantation, Key Laboratory of the Diagnosis and Treatment of Organ Transplantation, CAMS, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China Key Laboratory of Organ Transplantation, Zhejiang Province, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorShuping Que M.D., Shuping Que M.D. DingXiang Clinics, Hangzhou, ChinaSearch for more papers by this authorYong He B.S., Yong He B.S. NHC Key Laboratory of Combined Multi-organ Transplantation, Key Laboratory of the Diagnosis and Treatment of Organ Transplantation, CAMS, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China Key Laboratory of Organ Transplantation, Zhejiang Province, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorShusen Zheng M.D., Corresponding Author Shusen Zheng M.D. shusenzheng@zju.edu.cn Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China NHC Key Laboratory of Combined Multi-organ Transplantation, Key Laboratory of the Diagnosis and Treatment of Organ Transplantation, CAMS, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China Key Laboratory of Organ Transplantation, Zhejiang Province, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China Shulan Hospital (Hangzhou), Hangzhou, China Both authors contributed equally to this work. Address reprint requests to Zhengtao Liu, Ph.D., and Shusen Zheng, M.D., Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310 003, China. Telephone/FAX: +86 571 87236570; E-mail: liuzhengtao@zju.edu.cn; shusenzheng@zju.edu.cnSearch for more papers by this author Zhengtao Liu Ph.D., Corresponding Author Zhengtao Liu Ph.D. liuzhengtao@zju.edu.cn orcid.org/0000-0002-6232-4778 Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China NHC Key Laboratory of Combined Multi-organ Transplantation, Key Laboratory of the Diagnosis and Treatment of Organ Transplantation, CAMS, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China Key Laboratory of Organ Transplantation, Zhejiang Province, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China Both authors contributed equally to this work. Address reprint requests to Zhengtao Liu, Ph.D., and Shusen Zheng, M.D., Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310 003, China. Telephone/FAX: +86 571 87236570; E-mail: liuzhengtao@zju.edu.cn; shusenzheng@zju.edu.cnSearch for more papers by this authorWenchao Wang M.D., Wenchao Wang M.D. NHC Key Laboratory of Combined Multi-organ Transplantation, Key Laboratory of the Diagnosis and Treatment of Organ Transplantation, CAMS, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China Key Laboratory of Organ Transplantation, Zhejiang Province, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorShuping Que M.D., Shuping Que M.D. DingXiang Clinics, Hangzhou, ChinaSearch for more papers by this authorYong He B.S., Yong He B.S. NHC Key Laboratory of Combined Multi-organ Transplantation, Key Laboratory of the Diagnosis and Treatment of Organ Transplantation, CAMS, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China Key Laboratory of Organ Transplantation, Zhejiang Province, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, ChinaSearch for more papers by this authorShusen Zheng M.D., Corresponding Author Shusen Zheng M.D. shusenzheng@zju.edu.cn Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China NHC Key Laboratory of Combined Multi-organ Transplantation, Key Laboratory of the Diagnosis and Treatment of Organ Transplantation, CAMS, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China Key Laboratory of Organ Transplantation, Zhejiang Province, First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China Shulan Hospital (Hangzhou), Hangzhou, China Both authors contributed equally to this work. Address reprint requests to Zhengtao Liu, Ph.D., and Shusen Zheng, M.D., Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, No. 79 Qingchun Road, Hangzhou, 310 003, China. Telephone/FAX: +86 571 87236570; E-mail: liuzhengtao@zju.edu.cn; shusenzheng@zju.edu.cnSearch for more papers by this author First published: 09 October 2020 https://doi.org/10.1002/lt.25916 This study is supported by Innovative Research Groups of National Natural Science Foundation of China (81721091), Major Program of National Natural Science Foundation of China (91542205), National S&T Major Project (2017ZX10203205), National Natural Science Foundation of China (81902813), Zhejiang International Science and Technology Cooperation Project (2016C04003), Zhejiang Provincial Natural Science Foundation of China (LY18H030002), Zhejiang Medical Association (2019ZYC-A81), International Youth Exchange Programme by China Association for Science and Technology (2019), Tianqing Liver Diseases Research Fund (TQGB20200114), and Open Fund of Key Laboratory of High-Incidence-Tumor Prevention & Treatment (Guangxi Medical University), Ministry of Education. Potential conflict of interest: Nothing to report. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinked InRedditWechat No abstract is available for this article. Volume27, Issue3March 2021Pages 459-460 RelatedInformation

Letter to the Editor: HBeAg Expression Suppressing/abolishing Mutation Elevated HBV DNA Level in HBeAg‐negative Patients with Chronic HBV Infection

Epidemiological analysis of serum HBV DNA level among 13 039 patients with Hepatitis B

[Relationship between the quantitative results of HBV DNA and HBV markers (HBV M) in population with low-level HBsAg].

Biopsy‐based Single‐cell Transcriptomics Reveals MAIT Cells As Potential Targets for Controlling Fibrosis‐related Liver Inflammation Due to Chronic Hepatitis‐b Infection

HBsAg Levels in HBeAg-positive Chronic Hepatitis B Patients with Different Immune Conditions.

Liver Histopathological Features Influencing HBeAg Seroconversion in Patients with HBeAg-positive Chronic Hepatitis B Responding to Peg-IFN Treatment

A Potential Functional Cure In Chinese Hbeag-Negative Chronic Hepatitis B Patients Treated With Peg-Interferon Alpha-2a

Hepatitis B surface antigen levels during natural history of chronic hepatitis B: a Chinese perspective study.

HBsAg as an important predictor of HBeAg seroconversion following antiviral treatment for HBeAg-positive chronic hepatitis B patients

Liver histopathological lesions is severe in patients with normal alanine transaminase and low to moderate hepatitis B virus DNA replication

Is the Life‐long Entecavir Treatment Really Inevitable in Chronic Hepatitis B Patients?

Hepatitis B virus enhancer 1 activates preS1 and preS2 promoters of integrated HBV DNA impairing HBsAg secretion

Reply to the Letter by Jeng Et Al. ‘discrepant Range of Spd‐1 in Different Studies of Chronic Hepatitis B’

HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients

The Association of HBV Core Promoter Double Mutations (A1762T and G1764A) with Viral Load Differs Between HBeAg Positive and Anti-Hbe Positive Individuals: A Longitudinal Analysis

Prevalence and clinical characteristics of hepatitis B surface antigen-negative/hepatitis B core antibody-positive patients with detectable serum hepatitis B virus DNA

The impact of hepatitis B surface antigen on natural killer cells in patients with chronic hepatitis B virus infection

Letter to the Editor: the Role of Aquaporin 9 in Modeling of Ornithine Transcarbamylase Deficiency

Favourable Prognosis of Patients with Untreated HBeAg-Negative Chronic Hepatitis B Virus Infection with HBsAg < 100 IU/mL.

Presence of Macrosteatosis in Vivo Determined the Survival Status of Rats after Liver Transplantation

Clinical outcomes of treatment-naïve HBeAg-negative patients with chronic hepatitis B virus infection with low serum HBsAg and undetectable HBV DNA